PortalPublikationenPrevalence of metabolic syndrome in female and male patients...

Prevalence of metabolic syndrome in female and male patients at risk of psychosis

Standard

Prevalence of metabolic syndrome in female and male patients at risk of psychosis. / Cordes, Joachim; Bechdolf, Andreas; Engelke, Christina; Kahl, Kai G; Balijepalli, Chakrapani; Lösch, Christian; Klosterkötter, Joachim; Wagner, Michael; Maier, Wolfgang; Heinz, Andreas; de Millas, Walter; Gaebel, Wolfgang; Winterer, Georg; Janssen, Birgit; Schmidt-Kraepelin, Christian; Schneider, Frank; Lambert, Martin; Juckel, Georg; Wobrock, Thomas; Riedel, Michael; Moebus, Susanne.

in: SCHIZOPHR RES, Jahrgang 181, 03.2017, S. 38-42.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Cordes, J, Bechdolf, A, Engelke, C, Kahl, KG, Balijepalli, C, Lösch, C, Klosterkötter, J, Wagner, M, Maier, W, Heinz, A, de Millas, W, Gaebel, W, Winterer, G, Janssen, B, Schmidt-Kraepelin, C, Schneider, F, Lambert, M, Juckel, G, Wobrock, T, Riedel, M & Moebus, S 2017, 'Prevalence of metabolic syndrome in female and male patients at risk of psychosis', SCHIZOPHR RES, Jg. 181, S. 38-42. https://doi.org/10.1016/j.schres.2016.09.012

APA

Cordes, J., Bechdolf, A., Engelke, C., Kahl, K. G., Balijepalli, C., Lösch, C., Klosterkötter, J., Wagner, M., Maier, W., Heinz, A., de Millas, W., Gaebel, W., Winterer, G., Janssen, B., Schmidt-Kraepelin, C., Schneider, F., Lambert, M., Juckel, G., Wobrock, T., ... Moebus, S. (2017). Prevalence of metabolic syndrome in female and male patients at risk of psychosis. SCHIZOPHR RES, 181, 38-42. https://doi.org/10.1016/j.schres.2016.09.012

Vancouver

Cordes J, Bechdolf A, Engelke C, Kahl KG, Balijepalli C, Lösch C et al. Prevalence of metabolic syndrome in female and male patients at risk of psychosis. SCHIZOPHR RES. 2017 Mär;181:38-42. https://doi.org/10.1016/j.schres.2016.09.012

Bibtex

@article{3ef269bd805b4599b362508247ddfee7,
title = "Prevalence of metabolic syndrome in female and male patients at risk of psychosis",
abstract = "Metabolic Syndrome (MetS) is one of the most common factors underlying the high rate of mortality observed in patients with schizophrenia. Recent research on this topic revealed that many of the patients studied were, in fact, in a medicated state. As such, it is unclear whether MetS is causally associated with the disorder itself or the medication used to treat it. In this study, patients with a clinically high risk of expressing first episode psychosis (CHR) were examined regarding the prevalence of MetS. N=144 unmedicated and antipsychotic-na{\"i}ve CHR patients, aged between 18 and 42years and suffering from unmanifested prodromal symptoms, were compared with a cohort of N=3995 individuals from the {"}German Metabolic and Cardiovascular Risk Study{"} (GEMCAS). A slightly higher prevalence of individual MetS criteria was observed in the CHR group compared to the GEMCAS sample; specifically, the following were noted: a higher blood pressure (35.0% vs. 28.0%), increased waist circumference (17.6% vs. 15.1%), and increased fasting blood glucose (9.4% vs. 4.0%) in CHR patients. Additionally, the rate of reduced HDL cholesterol concentrations was lower in the control group (20.2% vs. 13.3%).",
author = "Joachim Cordes and Andreas Bechdolf and Christina Engelke and Kahl, {Kai G} and Chakrapani Balijepalli and Christian L{\"o}sch and Joachim Klosterk{\"o}tter and Michael Wagner and Wolfgang Maier and Andreas Heinz and {de Millas}, Walter and Wolfgang Gaebel and Georg Winterer and Birgit Janssen and Christian Schmidt-Kraepelin and Frank Schneider and Martin Lambert and Georg Juckel and Thomas Wobrock and Michael Riedel and Susanne Moebus",
note = "Copyright {\textcopyright} 2016 Elsevier B.V. All rights reserved.",
year = "2017",
month = mar,
doi = "10.1016/j.schres.2016.09.012",
language = "English",
volume = "181",
pages = "38--42",
journal = "SCHIZOPHR RES",
issn = "0920-9964",
publisher = "Elsevier",

}

RIS

TY - JOUR

T1 - Prevalence of metabolic syndrome in female and male patients at risk of psychosis

AU - Cordes, Joachim

AU - Bechdolf, Andreas

AU - Engelke, Christina

AU - Kahl, Kai G

AU - Balijepalli, Chakrapani

AU - Lösch, Christian

AU - Klosterkötter, Joachim

AU - Wagner, Michael

AU - Maier, Wolfgang

AU - Heinz, Andreas

AU - de Millas, Walter

AU - Gaebel, Wolfgang

AU - Winterer, Georg

AU - Janssen, Birgit

AU - Schmidt-Kraepelin, Christian

AU - Schneider, Frank

AU - Lambert, Martin

AU - Juckel, Georg

AU - Wobrock, Thomas

AU - Riedel, Michael

AU - Moebus, Susanne

N1 - Copyright © 2016 Elsevier B.V. All rights reserved.

PY - 2017/3

Y1 - 2017/3

N2 - Metabolic Syndrome (MetS) is one of the most common factors underlying the high rate of mortality observed in patients with schizophrenia. Recent research on this topic revealed that many of the patients studied were, in fact, in a medicated state. As such, it is unclear whether MetS is causally associated with the disorder itself or the medication used to treat it. In this study, patients with a clinically high risk of expressing first episode psychosis (CHR) were examined regarding the prevalence of MetS. N=144 unmedicated and antipsychotic-naïve CHR patients, aged between 18 and 42years and suffering from unmanifested prodromal symptoms, were compared with a cohort of N=3995 individuals from the "German Metabolic and Cardiovascular Risk Study" (GEMCAS). A slightly higher prevalence of individual MetS criteria was observed in the CHR group compared to the GEMCAS sample; specifically, the following were noted: a higher blood pressure (35.0% vs. 28.0%), increased waist circumference (17.6% vs. 15.1%), and increased fasting blood glucose (9.4% vs. 4.0%) in CHR patients. Additionally, the rate of reduced HDL cholesterol concentrations was lower in the control group (20.2% vs. 13.3%).

AB - Metabolic Syndrome (MetS) is one of the most common factors underlying the high rate of mortality observed in patients with schizophrenia. Recent research on this topic revealed that many of the patients studied were, in fact, in a medicated state. As such, it is unclear whether MetS is causally associated with the disorder itself or the medication used to treat it. In this study, patients with a clinically high risk of expressing first episode psychosis (CHR) were examined regarding the prevalence of MetS. N=144 unmedicated and antipsychotic-naïve CHR patients, aged between 18 and 42years and suffering from unmanifested prodromal symptoms, were compared with a cohort of N=3995 individuals from the "German Metabolic and Cardiovascular Risk Study" (GEMCAS). A slightly higher prevalence of individual MetS criteria was observed in the CHR group compared to the GEMCAS sample; specifically, the following were noted: a higher blood pressure (35.0% vs. 28.0%), increased waist circumference (17.6% vs. 15.1%), and increased fasting blood glucose (9.4% vs. 4.0%) in CHR patients. Additionally, the rate of reduced HDL cholesterol concentrations was lower in the control group (20.2% vs. 13.3%).

U2 - 10.1016/j.schres.2016.09.012

DO - 10.1016/j.schres.2016.09.012

M3 - SCORING: Journal article

C2 - 27751654

VL - 181

SP - 38

EP - 42

JO - SCHIZOPHR RES

JF - SCHIZOPHR RES

SN - 0920-9964

ER -